Hegazy Sahar Kmal, Tharwat Samar, Hassan Ahmed Hosny
Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta 31511, Egypt.
Rheumatology and Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura university, Mansoura 35511, Egypt.
World J Clin Cases. 2023 Sep 16;11(26):6105-6121. doi: 10.12998/wjcc.v11.i26.6105.
Coronavirus disease 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021-year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipiravir.
To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing the need for invasive mechanical ventilation (IMV).
265 COVID-19 polymerase chain reaction confirmed patients with indication for antiviral therapy were included in this study and were divided into 3 groups (1: 2: 2): Group A: REGN3048-3051 antibodies cocktail (casirivimab and imdevimab), group B: Remdesivir, group C: Favipiravir. The study design is a single-blind non-randomized controlled trial Mansoura University Hospital owns the study's drugs. The duration of the study was about 6 mo after ethical approval.
Casirivimab and imdevimab achieve less need for O therapy and IMV, with less duration of this need than remdesivir and favipiravir.
Group A (casirivimab and imdevimab) achieve better clinical outcomes than groups B (remdesivir) and C (favipiravir) intervention groups.
2019年冠状病毒病（COVID-19）大流行促使从2020年初至今开展了多项研究工作以找到应对这一危机的解决方案。随着2021年的结束，针对COVID-19的药物治疗出现了各种进展。在抗病毒治疗方面，卡西瑞维单抗和英地维单抗抗体组合是一种针对COVID-19的新型免疫疗法。针对COVID-19的标准抗病毒治疗包括瑞德西韦和法匹拉韦。
评估抗体鸡尾酒疗法（卡西瑞维单抗和英地维单抗）与标准抗病毒治疗相比在减少有创机械通气（IMV）需求方面的疗效。
本研究纳入了265例经COVID-19聚合酶链反应确诊且有抗病毒治疗指征的患者，并将其分为3组（1∶2∶2）：A组：REGN3048 - 3051抗体鸡尾酒疗法（卡西瑞维单抗和英地维单抗），B组：瑞德西韦，C组：法匹拉韦。该研究设计为单盲非随机对照试验。曼苏拉大学医院拥有该研究的药物。在获得伦理批准后，研究持续时间约为6个月。
与瑞德西韦和法匹拉韦相比，卡西瑞维单抗和英地维单抗对氧疗和IMV的需求更少，且这种需求的持续时间更短。
A组（卡西瑞维单抗和英地维单抗）比B组（瑞德西韦）和C组（法匹拉韦）干预组取得了更好的临床效果。
